Baris, V. O. Et Al. 2021. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways. CARDIOVASCULAR TOXICOLOGY , vol.21, no.9 , 747-758.

Baris, V. O., DİNÇSOY, A. B., GEDİKLİ, E., ZIRH, S., Muftuoglu, S. F., & ERDEM, A., (2021). Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways. CARDIOVASCULAR TOXICOLOGY , vol.21, no.9, 747-758.

Baris, Veysel Et Al. "Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways," CARDIOVASCULAR TOXICOLOGY , vol.21, no.9, 747-758, 2021

Baris, Veysel O. Et Al. "Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways." CARDIOVASCULAR TOXICOLOGY , vol.21, no.9, pp.747-758, 2021

Baris, V. O. Et Al. (2021) . "Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways." CARDIOVASCULAR TOXICOLOGY , vol.21, no.9, pp.747-758.

@article{article, author={Veysel Ozgur Baris Et Al. }, title={Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways}, journal={CARDIOVASCULAR TOXICOLOGY}, year=2021, pages={747-758} }